Candriam S.C.A. Esperion Therapeutics, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ESPR
# of Institutions
206Shares Held
128MCall Options Held
1.63MPut Options Held
930K-
Wasatch Advisors Inc Salt Lake City, UT23.3MShares$49 Million0.19% of portfolio
-
Black Rock Inc. New York, NY14MShares$29.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$27.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$20.9 Million0.28% of portfolio
-
Two Seas Capital LP Rye, NY6.58MShares$13.8 Million3.65% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $140M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...